Why Gilead Sciences Is Now A Hold (Rating Upgrade)
Gilead Sciences has received a rating upgrade to 'Hold' following a strong Q1 performance. The company's revenue increased significantly, driven by products like Trodelvy, Livdelzi, and Yeztugo. However, challenges remain in their cell therapy segment, which has not performed as well.
- ▪Gilead Sciences reported a revenue of $701 million in Q1, marking a 110% increase quarter-over-quarter.
- ▪The growth was primarily attributed to the success of Trodelvy, Livdelzi, and Yeztugo.
- ▪Despite the positive revenue growth, Gilead's cell therapy products have lagged behind expectations.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907521-why-gilead-sciences-is-now-a-hold-rating-upgrade"},"author":{"@type":"Person","name":"ALLKA…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
